Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Suhr, Caroline
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors	Recruiting	2	60	Europe, US, RoW	IO102-IO103, Pembrolizumab KEYTRUDA®	IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC	Melanoma, Squamous Cell Carcinoma of Head and Neck	04/25	01/27